PT - JOURNAL ARTICLE AU - Lenin Dominguez-Ramirez AU - Francisco Rodriguez-Perez AU - Francisca Sosa-Jurado AU - Gerardo Santos-Lopez AU - Paulina Cortes-Hernandez TI - The role of metabolic comorbidity in COVID-19 mortality of middle-aged adults. The case of Mexico AID - 10.1101/2020.12.15.20244160 DP - 2020 Jan 01 TA - medRxiv PG - 2020.12.15.20244160 4099 - http://medrxiv.org/content/early/2020/12/16/2020.12.15.20244160.short 4100 - http://medrxiv.org/content/early/2020/12/16/2020.12.15.20244160.full AB - Background In contrast to developed countries, in Mexico more than half of COVID-19 deaths have occurred in adults <65-years-old, with at least a million years of life lost to premature mortality (YLL) in eight months. Mexico has a young population but a high prevalence of metabolic diseases like obesity and diabetes that contribute to COVID-19 adverse outcomes. COVID-19 could be particularly risky in population with specific comorbidity combinations that haven’t been analyzed.Methods To explore what contributes to the high COVID-19 mortality in Mexican middle-aged adults, we calculated age-stratified COVID-19 case fatality rates, YLL and relative risk (RR) of 9 comorbidities and 23 comorbidity combinations in a retrospective Mexican cohort with 905,579 PCR-confirmed COVID-19 cases/89,167 deaths, until Nov/2/2020.Findings Chronic kidney disease (CKD) had the highest RR for COVID-19 fatality, followed by diabetes and immunosuppression, that in turn had higher RR than obesity or hypertension as single comorbidities. The combination diabetes/hypertension with or without obesity had RR as high as CKD as a single comorbidity (>3 in <60-year-olds). Notably, the RR of comorbidities decreased with age, tending to values near 1 after age 60; suggesting that in Mexico, comorbidities increase COVID-19 fatality mostly in young and middle-aged adults. Our analysis suggests that advanced metabolic disease, marked by multimorbidity (more than one chronic disease per individual) or diabetes before age 60, contribute particularly to the younger age of COVID-19 fatalities in Mexico. Around 38% of YLL to COVID-19, were attributable to the synergy between COVID-19 and pre-existing diseases, mainly combinations between obesity, diabetes and hypertension. Yet, ¼ of deaths and 1/3 of YLL have occurred in individuals without known comorbidities.Conclusions The Mexican COVID-19 outbreak illustrates that middle-aged adults 45-64-yo can have high COVID-19 mortality during large outbreaks, especially if they present chronic metabolic comorbidities, but also in their absence, making them an important group of concern after elders. COVID-19 mortality in middle-aged adults is likely proportional to the gradual decline in health that accompanies ageing, which presents earlier in poorer populations that also get more exposed to SARS-CoV-2 and have less access to specialized medical attention.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The authors are researchers at Instituto Mexicano del Seguro Social, that has ethics committees supervised by the federal authority in the country (Mexico). The manuscript analyzes datasets that are publicly available and where no individual patient information is distinguishable, thus the research is exempt from informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the data used in this study is hosted by the mexican government here: https://www.gob.mx/salud/documentos/datos-abiertos-152127 It is updated daily. https://www.gob.mx/salud/documentos/datos-abiertos-152127